Trogenix CEO Ken Macnamara (L) and CSO Steve Pollard

Ex­clu­sive: Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

Tro­genix has emerged from stealth to ad­vance its pipeline of vi­ral im­munother­a­pies for can­cer, start­ing with a lead can­di­date tar­get­ing an ag­gres­sive type of brain …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.